Portal Hypertension: Drug Development Pipeline Study, H1 2018
Portal Hypertension pipeline comprises of 8 drugs under development as of March 2018. Of these, 2 drugs are in Phase 1 and 5 drugs in phase 2 with no drugs in Phase 3. Further, 1 drug is in Pre-IND stage.
18 companies are developing the pipeline for Portal Hypertension. Of this, LinXis B.V. has the most recent stage drug in pipeline. 8 different mechanisms are being targeted for treatment of the condition.
Portal hypertension is the major cause for morbidity and mortality witnessed in patients suffering from liver cirrhosis. The condition is characterized by an increase in blood pressure levels in the portal venous system. It is one of the catastrophic complications associated with liver cirrhosis. As the vessels in the liver are blocked, blood does not smoothly pass through liver, resulting in elevated blood pressure. This results in growth of large and swollen veins in esophagus, stomach, rectum and umbilical areas.
The most comprehensive pipeline review “Portal Hypertension- Drug Development Pipeline Study” provides in-depth analysis and update information on Portal Hypertension pipeline drugs. Current status of all the drugs in the Portal Hypertension pipeline is provided in the research work.
The report provides detailed analysis of Portal Hypertension pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Portal Hypertension report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Portal Hypertension industry.
Scope:
18 companies are developing the pipeline for Portal Hypertension. Of this, LinXis B.V. has the most recent stage drug in pipeline. 8 different mechanisms are being targeted for treatment of the condition.
Portal hypertension is the major cause for morbidity and mortality witnessed in patients suffering from liver cirrhosis. The condition is characterized by an increase in blood pressure levels in the portal venous system. It is one of the catastrophic complications associated with liver cirrhosis. As the vessels in the liver are blocked, blood does not smoothly pass through liver, resulting in elevated blood pressure. This results in growth of large and swollen veins in esophagus, stomach, rectum and umbilical areas.
The most comprehensive pipeline review “Portal Hypertension- Drug Development Pipeline Study” provides in-depth analysis and update information on Portal Hypertension pipeline drugs. Current status of all the drugs in the Portal Hypertension pipeline is provided in the research work.
The report provides detailed analysis of Portal Hypertension pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Portal Hypertension report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Portal Hypertension industry.
Scope:
- - All latest industry developments and their impact on projects and companies
- - Complete overview of global Portal Hypertension therapy options and treatments
- - The pipeline study reviews drug details for Portal Hypertension by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- - Mergers, Acquisitions, licensing, co-development and project acquisition news for Portal Hypertension market
- - Portal Hypertension drugs being developed in combination with other drugs are also detailed
- - Company wise drugs listed with their current status, partners and news updates
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 PORTAL HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS
3.1 Conatus Pharmaceuticals PIPELINE, H1 2018
3.2 Cumberland Pharmaceuticals PIPELINE, H1 2018
3.3 Galectin Therapeutics PIPELINE, H1 2018
3.4 Mezzion Pharma Co. Ltd. PIPELINE, H1 2018
3.5 LinXis B.V. PIPELINE, H1 2018
3.6 Novartis Pharmaceuticals PIPELINE, H1 2018
3.7 Ono Pharmaceuticals PIPELINE, H1 2018
3.8 Ferring Pharmaceuticals PIPELINE, H1 2018
4 PORTAL HYPERTENSION DRUG SNAPSHOTS
4.1 Emricasan Drug Details
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Details
4.2 Portaban Drug Details
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Trial Details
4.3 GR-MD-02 Drug Details
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.3.5 Trial Details
4.4 Udenafil Drug Details
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Trial Details
4.5 LxL-001 Drug Details
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.6 Serelaxin Drug Details
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Trial Details
4.7 ONO 1266 Drug Details
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.7.5 Trial Details
4.8 FE 204205 Drug Details
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial Details
5 APPENDIX
5.1 ABOUT VPA RESEARCH
5.2 SOURCES AND RESEARCH METHODOLOGY
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 PORTAL HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS
3.1 Conatus Pharmaceuticals PIPELINE, H1 2018
3.2 Cumberland Pharmaceuticals PIPELINE, H1 2018
3.3 Galectin Therapeutics PIPELINE, H1 2018
3.4 Mezzion Pharma Co. Ltd. PIPELINE, H1 2018
3.5 LinXis B.V. PIPELINE, H1 2018
3.6 Novartis Pharmaceuticals PIPELINE, H1 2018
3.7 Ono Pharmaceuticals PIPELINE, H1 2018
3.8 Ferring Pharmaceuticals PIPELINE, H1 2018
4 PORTAL HYPERTENSION DRUG SNAPSHOTS
4.1 Emricasan Drug Details
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Details
4.2 Portaban Drug Details
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Trial Details
4.3 GR-MD-02 Drug Details
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.3.5 Trial Details
4.4 Udenafil Drug Details
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Trial Details
4.5 LxL-001 Drug Details
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.6 Serelaxin Drug Details
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Trial Details
4.7 ONO 1266 Drug Details
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.7.5 Trial Details
4.8 FE 204205 Drug Details
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial Details
5 APPENDIX
5.1 ABOUT VPA RESEARCH
5.2 SOURCES AND RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Portal Hypertension Pipeline by Phase, H1- 2018
Figure 2: Portal Hypertension Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Portal Hypertension Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
Figure 1: Portal Hypertension Pipeline by Phase, H1- 2018
Figure 2: Portal Hypertension Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Portal Hypertension Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Portal Hypertension Pipeline by Phase, H1- 2018
Table 2: Portal Hypertension Pipeline by Companies, H1- 2018 (1)
Table 3: Portal Hypertension Pipeline by Mechanism of Action, H1- 2018
Table 4: Conatus Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018
Table 5: Cumberland Pharmaceuticals Portal Hypertension Pipeline, H1- 2018
Table 6: Galectin Therapeutics Portal Hypertension Pipeline, H1- 2018
Table 7: Mezzion Pharma Co. Ltd. - Portal Hypertension Pipeline, H1- 2018
Table 8: LinXis B.V. - Portal Hypertension Pipeline, H1- 2018
Table 9: Novartis Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018
Table 10: Ono Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018
Table 11: Ferring Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018
Table 1: Portal Hypertension Pipeline by Phase, H1- 2018
Table 2: Portal Hypertension Pipeline by Companies, H1- 2018 (1)
Table 3: Portal Hypertension Pipeline by Mechanism of Action, H1- 2018
Table 4: Conatus Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018
Table 5: Cumberland Pharmaceuticals Portal Hypertension Pipeline, H1- 2018
Table 6: Galectin Therapeutics Portal Hypertension Pipeline, H1- 2018
Table 7: Mezzion Pharma Co. Ltd. - Portal Hypertension Pipeline, H1- 2018
Table 8: LinXis B.V. - Portal Hypertension Pipeline, H1- 2018
Table 9: Novartis Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018
Table 10: Ono Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018
Table 11: Ferring Pharmaceuticals - Portal Hypertension Pipeline, H1- 2018
